@article{3f53541893ce492b986fc3d3a7094a4e,
title = "IL-6 effector function of group 2 innate lymphoid cells (ILC2) is NOD2 dependent",
abstract = "Cutaneous group 2 innate lymphoid cells (ILC2) are spatially and epigenetically poised to respond to barrier compromise and associated immunological threats. ILC2, lacking rearranged antigen-specific receptors, are primarily activated by damage-associated cytokines and respond with type 2 cytokine production. To investigate ILC2 potential for direct sensing of skin pathogens and allergens, we performed RNA sequencing of ILC2 derived from in vivo challenged human skin or blood. We detected expression of NOD2 and TLR2 by skin and blood ILC2. Stimulation of ILC2 with TLR2 agonist alone not only induced interleukin-5 (IL-5) and IL-13 expression but also elicited IL-6 expression in combination with Staphylococcus aureus muramyl dipeptide (MDP). Heat-killed skin-resident bacteria provoked an IL-6 profile in ILC2 in vitro that was notably impaired in ILC2 derived from patients with nucleotide-binding oligomerization domain-containing protein 2 (NOD2) mutations. In addition, we show that NOD2 signaling can stimulate autophagy in ILC2, which was also impaired in patients with NOD2 mutations. Here, we have identified a role for ILC2 NOD2 signaling in the differential regulation of ILC2-derived IL-6 and have reported a previously unrecognized pathway of direct ILC2 bacterial sensing. ",
author = "Hardman, \{Clare S.\} and Chen, \{Yi Ling\} and Maryam Salimi and Janina Nahler and Daniele Corridoni and Marta Jagielowicz and Fonseka, \{Chathuranga L.\} and David Johnson and Emmanouela Repapi and Cousins, \{David J.\} and Barlow, \{Jillian L.\} and McKenzie, \{Andrew N.J.\} and Alison Simmons and Graham Ogg",
note = "Funding Information: We acknowledge the support of the National Institute for Health Research Clinical Research Network, British Association of Dermatologists, British Skin Foundation, and Misses Barrie Charitable Trust. This work was funded by the Medical Research Council (CF7720, U105178805, and MR/K018779/1) and the Wellcome Trust (090532/Z/09/Z) and supported by the NIHR (NIHR) Oxford Biomedical Research Centre (BRC). D.J.C. acknowledges support from the NIHR Leicester Biomedical Research Centre. A.S. was supported by an NIHR Senior Investigator Award and Wellcome Investigator Award. D.C. was supported by Crohn's and Colitis UK. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. Publisher Copyright: Copyright {\textcopyright} 2021 The Authors, some rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = may,
doi = "10.1126/sciimmunol.abe5084",
language = "English",
volume = "6",
journal = "Science Immunology",
issn = "2470-9468",
publisher = "American Association for the Advancement of Science",
number = "59",
}